BioTime, Inc. (BTX) Receives Average Recommendation of “Hold” from Brokerages

Shares of BioTime, Inc. (NYSEMKT:BTX) have earned an average recommendation of “Hold” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating and two have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $6.25.

Several equities research analysts recently issued reports on BTX shares. Zacks Investment Research upgraded shares of BioTime from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research report on Tuesday, July 18th. ValuEngine cut shares of BioTime from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, BidaskClub cut shares of BioTime from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th.

COPYRIGHT VIOLATION WARNING: “BioTime, Inc. (BTX) Receives Average Recommendation of “Hold” from Brokerages” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/11/06/biotime-inc-btx-receives-average-recommendation-of-hold-from-brokerages.html.

BioTime (BTX) traded down $0.04 on Wednesday, reaching $2.37. 68,629 shares of the company’s stock traded hands, compared to its average volume of 429,124. BioTime has a fifty-two week low of $2.27 and a fifty-two week high of $3.96.

In related news, Director Broadwood Partners, L.P. acquired 2,692,307 shares of the business’s stock in a transaction on Friday, October 13th. The shares were bought at an average price of $2.60 per share, with a total value of $6,999,998.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders have acquired 2,716,203 shares of company stock worth $7,061,218.

A number of institutional investors and hedge funds have recently made changes to their positions in BTX. Vanguard Group Inc. boosted its position in shares of BioTime by 17.0% during the 2nd quarter. Vanguard Group Inc. now owns 3,680,705 shares of the biotechnology company’s stock worth $11,594,000 after purchasing an additional 534,527 shares in the last quarter. State Street Corp boosted its position in shares of BioTime by 10.3% during the 2nd quarter. State Street Corp now owns 1,345,379 shares of the biotechnology company’s stock worth $4,238,000 after purchasing an additional 125,833 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of BioTime by 159.5% during the 1st quarter. Geode Capital Management LLC now owns 1,043,378 shares of the biotechnology company’s stock worth $3,599,000 after purchasing an additional 641,358 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of BioTime by 6.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 474,858 shares of the biotechnology company’s stock worth $1,496,000 after purchasing an additional 29,827 shares in the last quarter. Finally, IndexIQ Advisors LLC boosted its position in shares of BioTime by 83.1% during the 3rd quarter. IndexIQ Advisors LLC now owns 251,227 shares of the biotechnology company’s stock worth $713,000 after purchasing an additional 114,003 shares in the last quarter.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

What are top analysts saying about BioTime Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioTime Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit